Reuters reported May 5 ↗, citing IQVIA, that Novo Nordisk's Wegovy ↗ pill booked roughly 721,000 US prescriptions in Q1, beating analyst expectations on raw volume. The structural caveat: about 450,000 of those scripts were for the 1.5 mg starter dose at $149 per month, the cheapest tier of the GoodRx-published self-pay pricing. Wednesday's Novo Q1 print is the test of whether prescription momentum can offset the falling-price headwind that has cut more than $400 billion from the company's market value since 2024.
The volume-versus-price question. Novo set February 2026 guidance at a 5% to 13% decline in sales and operating profit at constant exchange rates, reflecting the price erosion accumulating across the GLP-1 class. The Wegovy pill 721K Q1 number is the strongest piece of volume data investors have ahead of today's print. Whether the company holds the February guidance, raises it on volume strength, or lowers it on continued price pressure is the inflection point. Each scenario carries a different read on the broader GLP-1 commercial structure.
The competitive context. The IQVIA Q1 number sits against the Foundayo Week 3 read of 5,612 weekly scripts ↗ the section covered May 4. Annualized at the most recent weekly run rate of about 113,000, Wegovy pill is on roughly a 5.9-million-prescription pace. The 721K Q1 number, run-rate-extended to a full year, lands in the 2.9 million range, which suggests the run rate accelerated through Q1 to reach the 113K weekly read. Either way, Wegovy pill is the dominant oral GLP-1 product by an order of magnitude or more, and the Foundayo launch ramp will need to reach 2026-Q4 before any direct comparison on commercial fundamentals is meaningful.
The price tier inside the volume. The 450,000 scripts at the 1.5 mg starter dose is the structurally important number. Patients on the starter dose pay $149 per month self-pay or roughly $25 per three months with insurance. They are also the population most likely to either move up to higher doses (raising the per-script revenue) or discontinue therapy entirely (removing the script from future quarters). The Q3 and Q4 picture depends on which way the starter-dose cohort migrates, and that question is downstream of GLP-1 tolerability, weight-loss outcomes, and the GoodRx-and-WW Med+ channel architecture Novo built around the launch.
What today's call has to clarify. Three concrete questions. First, whether revenue grew enough on volume to offset the price decline at constant exchange rates, or whether the 5% to 13% guidance was directionally correct. Second, whether direct-to-consumer NovoCare Pharmacy and the WeightWatchers Med+ plus GoodRx channel architecture is converting starter-dose patients into sustained users, or whether discontinuation rates run high enough to undermine the volume story. Third, what Novo says about CagriSema's Phase 3 trajectory, ECO 2026 data presentations (Istanbul May 12-15), and the petrelintide ↗ combination Phase 2 starting mid-2026, all of which were advanced last week ↗ but need management commentary to enter the analyst model.
The platform read. The GLP-1R ↗ target page anchors the section's metabolic-drug coverage. Wegovy pill (oral semaglutide ↗ for obesity) is a peptide product on the platform-relevant side of the GLP-1 commercial map; Foundayo (orforglipron) sits on the small-molecule side and is outside the platform's peptide focus. Novo's full Q1 print today determines whether the peptide-versus-small-molecule split in the oral GLP-1 category is a structural commercial advantage for Novo or whether Lilly's small-molecule cost-of-goods advantage will compress the gap over multiple quarters.
The European Congress on Obesity is May 12-15 in Istanbul. CagriSema REDEFINE 1 body composition data, the 21-expert global panel proposing a 10-year GLP-1 cancer-prevention trial ↗, and a new Nature Communications GLP-1 umbrella review (covered separately by the news section today) all converge on Istanbul as the next data and policy inflection point. Today's Novo Q1 print is the commercial setup for that two-week window.